Ventyx Biosciences, Inc. Common Stock
Symbol: VTYX (NASDAQ)
Company Description:
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $3.11
- Yesterday High: $3.18
- Yesterday Low: $2.965
- Yesterday Volume: 1.16M
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
- Name: Ventyx Biosciences, Inc. Common Stock
- Website: https://www.ventyxbio.com
- Listed Date: 2021-10-21
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001851194
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $215.71M
- Round Lot: 100
- Outstanding Shares: 71.31M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-07 | 10-Q | View |
2025-08-07 | 8-K | View |
2025-07-16 | SCHEDULE 13G/A | View |
2025-06-17 | 8-K | View |
2025-06-10 | 8-K | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-05-30 | SCHEDULE 13G | View |
2025-05-16 | 4 | View |
2025-05-16 | 4 | View |
2025-05-15 | SCHEDULE 13G/A | View |
2025-05-15 | SCHEDULE 13G/A | View |
2025-05-08 | 10-Q | View |
2025-05-08 | 8-K | View |
2025-04-23 | ARS | View |
2025-04-23 | DEFA14A | View |